BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30053382)

  • 1. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species.
    Vera-Puente O; Rodriguez-Antolin C; Salgado-Figueroa A; Michalska P; Pernia O; Reid BM; Rosas R; Garcia-Guede A; SacristÁn S; Jimenez J; Esteban-Rodriguez I; Martin ME; Sellers TA; León R; Gonzalez VM; De Castro J; Ibanez de Caceres I
    Transl Res; 2018 Oct; 200():1-17. PubMed ID: 30053382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15.
    Jia YC; Wang JY; Liu YY; Li B; Guo H; Zang AM
    Cell Biol Int; 2019 Apr; 43(4):384-393. PubMed ID: 30599080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).
    Gu Y; Zhang Z; Yin J; Ye J; Song Y; Liu H; Xiong Y; Lu M; Zheng G; He Z
    J Exp Clin Cancer Res; 2017 Aug; 36(1):114. PubMed ID: 28859669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
    Fang M; Hutchinson L; Deng A; Green MR
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1250-5. PubMed ID: 26787892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-128 Is Implicated in Stress Responses by Targeting MAFG in Skeletal Muscle Cells.
    Caggiano R; Cattaneo F; Moltedo O; Esposito G; Perrino C; Trimarco B; Ammendola R; Faraonio R
    Oxid Med Cell Longev; 2017; 2017():9308310. PubMed ID: 29138682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
    Xiang L; Zeng Q; Liu J; Xiao M; He D; Zhang Q; Xie D; Deng M; Zhu Y; Liu Y; Bo H; Liu X; Zhou M; Xiong W; Zhou Y; Zhou J; Li X; Cao K
    Sci Bull (Beijing); 2021 Sep; 66(17):1773-1788. PubMed ID: 36654385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
    Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
    Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MafG controls the hypoxic response of cells by accumulating HIF-1alpha in the nuclei.
    Ueda K; Xu J; Morimoto H; Kawabe A; Imaoka S
    FEBS Lett; 2008 Jul; 582(16):2357-64. PubMed ID: 18538669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P; Hou J; Yao M; Wu J; Ren G
    Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
    Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
    EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C; Meng F; Li Y; Jiang Y
    J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.